X0508 4 2023-08-23 1 0001814140 Apexigen, Inc. APGN 0001786723 Hsu Frank J. C/O APEXIGEN, INC. 900 INDUSTRIAL ROAD, SUITE C SAN CARLOS CA 94070 0 1 0 0 Chief Medical Officer 0 Common Stock 2023-08-23 4 D 0 16354 D 0 D Employee Stock Option (right to buy) 4.79 2023-08-23 4 D 0 224872 D 2032-01-23 Common Stock 224872 0 D Employee Stock Option (right to buy) 2.46 2023-08-23 4 D 0 27000 D 2032-10-07 Common Stock 27000 0 D Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), each share of Issuer common stock was exchanged for 0.1725 shares of Pyxis common stock and rounded down to the nearest whole share. One-fourth of the shares subject to the option vested on August 30, 2022 and 1/36th of the remaining shares vest monthly thereafter. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 38,789 shares of Pyxis common stock at an exercise price of $27.77 per share. The shares subject to the option vest in 48 equal monthly installments beginning on February 1, 2022. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 4,656 shares of Pyxis common stock at an exercise price of $14.27 per share. /s/ Francis Sarena, by power of attorney 2023-08-25